![](/images/graphics-bg.png)
Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review
Joint Authors
Rutherford, George
Balayan, Tatevik
Horvath, Hacsi
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-09-26
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
Darunavir is a second-generation protease-inhibitor used with ritonavir (DRV/r) and two nucleoside reverse-transcriptase inhibitors as an option in first-line antiretroviral treatment (ART).
Methods.
We systematically reviewed randomized controlled trials (RCTs) of DRV/r versus other regimens in patients initiating ART.
We searched five bibliographic databases and other key resources.
We had no language limitations.
We assessed bias risk with the Cochrane tool and used GRADE to assess evidence quality.
We report findings in terms of risk ratio (RR) with 95% confidence intervals (CI).
Findings.
Three RCTs met inclusion criteria.
In plasma viral load suppression, DRV/r outperformed ritonavir-boosted lopinavir at 48 weeks (RR 1.13, 95% CI 1.03–1.25), 96 weeks (RR 1.11, 95% CI 1.02–1.21), and 192 weeks (RR 1.20, 95% CI 1.07–1.35).
DRV/r was similar to dolutegravir at 48 weeks (RR 0.96, 95% CI 0.87–1.06) but less effective at 96 weeks (RR 0.84, 95% CI 0.75–0.93).
At 96 weeks, DRV/r underperformed raltegravir (RR 0.94, 95% CI 0.88–0.99) but was similar to ritonavir-boosted atazanavir (RR 1.02, 95% CI 0.96–1.09).
Overall bias risk was moderate.
Evidence quality was also moderate.
Interpretation.
Initial ART regimens using DRV/r should be considered in future World Health Organization guidelines.
American Psychological Association (APA)
Balayan, Tatevik& Horvath, Hacsi& Rutherford, George. 2017. Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review. AIDS Research and Treatment،Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1130915
Modern Language Association (MLA)
Balayan, Tatevik…[et al.]. Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review. AIDS Research and Treatment No. 2017 (2017), pp.1-9.
https://search.emarefa.net/detail/BIM-1130915
American Medical Association (AMA)
Balayan, Tatevik& Horvath, Hacsi& Rutherford, George. Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review. AIDS Research and Treatment. 2017. Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1130915
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1130915